Autor: |
Alberto Benussi, Ilenia Libri, Enrico Premi, Antonella Alberici, Valentina Cantoni, Yasmine Gadola, Jasmine Rivolta, Marta Pengo, Stefano Gazzina, Vince D. Calhoun, Roberto Gasparotti, Henrik Zetterberg, Nicholas J. Ashton, Kaj Blennow, Alessandro Padovani, Barbara Borroni |
Jazyk: |
angličtina |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022) |
Druh dokumentu: |
article |
ISSN: |
2352-8737 |
DOI: |
10.1002/trc2.12326 |
Popis: |
Abstract Introduction The possibility to generalize our understandings on treatments and assessments to both familial frontotemporal dementia (f‐FTD) and sporadic FTD (s‐FTD) is a fundamental perspective for the near future, considering the constant advancement in potential disease‐modifying therapies that target particular genetic forms of FTD. We aimed to investigate differences in clinical features, cerebrospinal fluid (CSF), and blood‐based biomarkers between f‐FTD and s‐FTD. Methods In this longitudinal cohort study, we evaluated a consecutive sample of symptomatic FTD patients, classified as f‐FTD and s‐FTD according to Goldman scores (GS). All patients underwent clinical, behavioral, and neuropsychiatric symptom assessment, CSF biomarkers and serum neurofilament light (NfL) analysis, and brain atrophy evaluation with magnetic resonance imaging. Results Of 570 patients with FTD, 123 were classified as f‐FTD, and 447 as s‐FTD. In the f‐FTD group, 95 had a pathogenic FTD mutation while 28 were classified as GS = 1 or 2; of the s‐FTD group, 133 were classified as GS = 3 and 314 with GS = 4. f‐FTD and s‐FTD cases showed comparable demographic features, except for younger age at disease onset, age at diagnosis, and higher years of education in the f‐FTD group (all P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|